GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

NCT03576131 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

48

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Colorectal Cancer
Non-small Cell Lung Cancer
Triple Negative Breast Cancer
Renal Cell Carcinoma
Gastric Cancer
Pancreatic Cancer
Urothelial Cancer

Interventions

BIOLOGICAL: GEN1029 (HexaBody®-DR5/DR5)

Sponsor

Genmab